|
DE134631T1
(de)
|
1983-06-15 |
1985-12-05 |
Roger Kingdom Craig |
Peptide, pharmazeutische zusammensetzungen, gene, vektoren, wirtorganismen, verfahren zu deren herstellung und diagnostische reagenzien.
|
|
JPS62129297A
(ja)
|
1985-08-09 |
1987-06-11 |
Toyo Jozo Co Ltd |
カルシトニン遺伝子関連ペプチド誘導体
|
|
JP3101690B2
(ja)
|
1987-03-18 |
2000-10-23 |
エス・ビィ・２・インコーポレイテッド |
変性抗体の、または変性抗体に関する改良
|
|
US5364841A
(en)
|
1988-01-11 |
1994-11-15 |
Amylin Pharmaceuticals, Inc. |
Treatment of obesity and essential hypertension and related disorders
|
|
US5266561A
(en)
|
1988-01-11 |
1993-11-30 |
Amylin Pharmaceuticals, Inc. |
Treatment of type 2 diabetes mellitus
|
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
|
US5116964A
(en)
|
1989-02-23 |
1992-05-26 |
Genentech, Inc. |
Hybrid immunoglobulins
|
|
DE69433747D1
(de)
|
1994-08-16 |
2004-06-03 |
Human Genome Sciences Inc |
Calcitoninrezeptor
|
|
FR2732221B1
(fr)
|
1995-03-28 |
1997-04-25 |
Oreal |
Utilisation d'un antagoniste de cgrp pour traiter les rougeurs cutanees d'origine neurogene et composition obtenue
|
|
EP0851759A4
(en)
|
1995-09-05 |
2000-12-06 |
Smithkline Beecham Corp |
COMPOUNDS AND RELATED METHODS
|
|
EP0934068A1
(en)
|
1996-09-09 |
1999-08-11 |
Smithkline Beecham Corporation |
Compounds and methods
|
|
DE59711622D1
(de)
|
1996-09-10 |
2004-06-17 |
Boehringer Ingelheim Pharma |
Abgewandelte aminosäuren, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
|
|
WO1998056779A1
(en)
|
1997-06-13 |
1998-12-17 |
Smithkline Beecham Corporation |
4-sulfinyl benzamides as calcitonin gene-related peptide receptor antagonists
|
|
US6956107B2
(en)
|
1998-02-20 |
2005-10-18 |
Tanox, Inc. |
Inhibitors of complement activation
|
|
JP2002525371A
(ja)
|
1998-09-30 |
2002-08-13 |
メルク シャープ エンド ドーム リミテッド |
Ｃｇｒｐリガンドとしてのベンゾイミダゾリニルピペリジン
|
|
AU1219000A
(en)
|
1998-10-22 |
2000-05-08 |
Regents Of The University Of California, The |
Functionally assembled antigen-specific intact recombinant antibody and a methodfor production thereof
|
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
EP1031350A1
(en)
|
1999-02-23 |
2000-08-30 |
Warner-Lambert Company |
Use of a gabapentin-analog for the manufacture of a medicament for preventing and treating visceral pain
|
|
US6313097B1
(en)
|
1999-03-02 |
2001-11-06 |
Boehringer Ingelheim Pharma Kg |
Antagonists of calcitonin gene-related peptide
|
|
US6521609B1
(en)
|
1999-08-10 |
2003-02-18 |
Boehringer Ingelheim Pharma Kg |
Use of CGRP antagonists and CGRP release inhibitors for combating menopausal hot flushes
|
|
WO2001022972A2
(en)
|
1999-09-25 |
2001-04-05 |
University Of Iowa Research Foundation |
Immunostimulatory nucleic acids
|
|
JP2003525061A
(ja)
|
2000-03-01 |
2003-08-26 |
メディミューン，インコーポレイテッド |
高効力組換え抗体およびその産生法
|
|
US6406863B1
(en)
|
2000-06-23 |
2002-06-18 |
Genetastix Corporation |
High throughput generation and screening of fully human antibody repertoire in yeast
|
|
US20020162125A1
(en)
|
2001-03-06 |
2002-10-31 |
Anne-Marie Salmon |
Methods and compositions for the modulation of neurogenic inflammatory pain and physical opiate withdrawal
|
|
US20030181462A1
(en)
|
2001-08-17 |
2003-09-25 |
Boehringer Ingelheim Pharma Kg |
Use of BIBN4096 in combination with other antimigraine drugs for the treatment of migraine
|
|
EP1461068A4
(en)
|
2001-11-26 |
2006-03-29 |
Protemix Corp Ltd |
METHOD AND COMPOSITIONS FOR NORMALIZING LIPID MIRRORS IN MIRACLE TISSUE
|
|
ES2327830T3
(es)
|
2002-03-29 |
2009-11-04 |
Schering Corporation |
Anticuerpos monoclonales humanos anti-interleuquina-5 y metodos y composiciones que los contienen.
|
|
US7879991B2
(en)
|
2002-05-06 |
2011-02-01 |
Noxxon Pharma Ag |
CGRP binding nucleic acids
|
|
US20040110170A1
(en)
|
2002-05-18 |
2004-06-10 |
The Regents Of The University Of California |
Cloning and characterization of calcitonin gene related peptide receptors
|
|
US7345065B2
(en)
|
2002-05-21 |
2008-03-18 |
Allergan, Inc. |
Methods and compositions for alleviating pain
|
|
ES2616539T3
(es)
|
2002-06-05 |
2017-06-13 |
Bristol-Myers Squibb Company |
Antagonistas de receptores de péptidos relacionados con el gen de calcitonina
|
|
CN1678634A
(zh)
|
2002-06-28 |
2005-10-05 |
多曼蒂斯有限公司 |
免疫球蛋白单个变体抗原结合区及其特异性构建体
|
|
MXPA05001649A
(es)
|
2002-08-12 |
2005-05-27 |
Birkir Sveinsson |
Uso de compuestos antagonistas del cgrp para tratamiento de la psoriasis.
|
|
UA80447C2
(en)
|
2002-10-08 |
2007-09-25 |
|
Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic
|
|
DE10250082A1
(de)
|
2002-10-25 |
2004-05-13 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
|
|
JP4754219B2
(ja)
|
2002-12-02 |
2011-08-24 |
アムジエン・フレモント・インコーポレイテツド |
腫瘍壊死因子を対象とする抗体、およびそれらの使用
|
|
DK1575517T3
(da)
|
2002-12-24 |
2012-05-14 |
Rinat Neuroscience Corp |
Anti-ngf-antistoffer og fremgangsmåder til anvendelse af samme
|
|
AU2004222328B2
(en)
|
2003-03-14 |
2009-10-08 |
Merck Sharp & Dohme Corp. |
Aryl spirohydantoin CGRP receptor antagonists
|
|
EP1606286B1
(en)
|
2003-03-14 |
2011-05-11 |
Merck Sharp & Dohme Corp. |
Benodiazepine spirohydantoin cgrp receptor antagonists
|
|
JP4673294B2
(ja)
|
2003-03-14 |
2011-04-20 |
メルク・シャープ・エンド・ドーム・コーポレイション |
二環式アニリドスピロヒダントインｃｇｒｐ受容体拮抗物質
|
|
EP1606264B1
(en)
|
2003-03-14 |
2012-05-02 |
Merck Sharp & Dohme Corp. |
Monocyclic anilide spirohydantoin cgrp receptor antagonists
|
|
US7288559B2
(en)
|
2003-03-14 |
2007-10-30 |
Merck + Co, Inc. |
Carboxamide spirohydantoin CGRP receptor antagonists
|
|
JO2355B1
(en)
|
2003-04-15 |
2006-12-12 |
ميرك شارب اند دوم كوربوريشن |
Hereditary calcitonin polypeptide receptor antagonists
|
|
WO2004091514A2
(en)
|
2003-04-15 |
2004-10-28 |
Merck & Co., Inc. |
Cgrp receptor antagonists
|
|
WO2004097421A2
(en)
|
2003-04-29 |
2004-11-11 |
Bayer Healthcare Ag |
Diagnostics and therapeutics for diseases associated with calcitonin receptor-like receptor (calcrl)
|
|
EP1644004A4
(en)
|
2003-06-20 |
2010-10-06 |
Ronald Aung-Din |
LOCAL THERAPY FOR THE TREATMENT OF MIGRAINS, MUSCLE CLARIFICATIONS, MUSCLE SPASMS, SPASTICITY AND RELATED CONDITIONS
|
|
EP1646611A1
(en)
|
2003-07-15 |
2006-04-19 |
Merck & Co., Inc. |
Hydroxypyridine cgrp receptor antagonists
|
|
DK1678314T3
(da)
|
2003-10-22 |
2012-12-03 |
Keck Graduate Inst |
Fremgangsmåde til syntetisering af heteromultimere polypeptider i gær ved anvendelse af en haploid parringsstrategi
|
|
WO2005041757A2
(en)
|
2003-10-29 |
2005-05-12 |
University Of Rochester |
Detection of neuropeptides associated with pelvic pain disorders and uses thereof
|
|
WO2005070444A2
(en)
|
2004-01-13 |
2005-08-04 |
Vasogenix Pharmaceuticals, Inc. |
Methods for treating acute myocardial infarction by calcitonin gene related peptide and compositions containing the same
|
|
DE102004015723A1
(de)
|
2004-03-29 |
2005-10-20 |
Boehringer Ingelheim Pharma |
Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
|
|
DE102004018794A1
(de)
|
2004-04-15 |
2005-10-27 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
|
|
US7279471B2
(en)
|
2004-04-15 |
2007-10-09 |
Boehringer Ingelheim International Gmbh |
Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
|
|
TWI432196B
(zh)
|
2005-01-18 |
2014-04-01 |
Euro Celtique Sa |
內臟痛的治療
|
|
EP1770091A1
(de)
|
2005-09-29 |
2007-04-04 |
Boehringer Ingelheim Pharma GmbH & Co. KG |
CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
|
|
ITRM20050290A1
(it)
|
2005-06-07 |
2006-12-08 |
Lay Line Genomics Spa |
Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato.
|
|
US20100144767A1
(en)
|
2005-08-25 |
2010-06-10 |
Wex Pharmaceuticals, Inc. |
Use of sodium channel blockers for the treatment of visceral pain or pain caused by cancer treatment
|
|
US8168592B2
(en)
|
2005-10-21 |
2012-05-01 |
Amgen Inc. |
CGRP peptide antagonists and conjugates
|
|
SI3045182T1
(en)
|
2005-11-14 |
2018-08-31 |
Teva Pharmaceuticals International Gmbh |
An antibody to a peptide-associated peptide antagonist to calcitonin for treating a headache in aggregates
|
|
US20070108378A1
(en)
|
2005-11-14 |
2007-05-17 |
Toru Terabayashi |
High pressure optical cell for a downhole optical fluid analyzer
|
|
CA2629406A1
(en)
|
2005-11-18 |
2007-05-31 |
Merck & Co., Inc. |
Spirohydantoin aryl cgrp receptor antagonists
|
|
WO2007076336A1
(en)
|
2005-12-22 |
2007-07-05 |
Eli Lilly And Company |
Treatment of migraine with anti-cgrp antibodies
|
|
US9074352B2
(en)
|
2006-03-27 |
2015-07-07 |
John R. Ramun |
Universal control scheme for mobile hydraulic equipment and method for achieving the same
|
|
WO2007141285A1
(en)
|
2006-06-08 |
2007-12-13 |
Boehringer Ingelheim International Gmbh |
Treatment of gastrointestinal disorders with cgrp-antagonists
|
|
JP5511379B2
(ja)
|
2006-07-21 |
2014-06-04 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
Ｃｇｒｐレセプターアンタゴニスト
|
|
NZ601583A
(en)
|
2007-05-21 |
2013-08-30 |
Bristol Myers Squibb Co |
Novel rabbit antibody humanization methods and humanized rabbit antibodies
|
|
DK2164514T3
(en)
|
2007-05-21 |
2017-02-27 |
Alderbio Holdings Llc |
Antibodies to IL-6 and its use
|
|
MX2010009724A
(es)
|
2008-03-04 |
2010-09-28 |
Pfizer Ltd |
Procedimientos de tratamiento del dolor inflamatorio-.
|
|
KR101304150B1
(ko)
|
2008-03-04 |
2013-09-05 |
라브리스 바이올로직스 인코포레이티드 |
만성 통증의 치료 방법
|
|
JO3382B1
(ar)
|
2008-12-23 |
2019-03-13 |
Amgen Inc |
أجسام مضادة ترتبط مع مستقبل cgrp بشري
|
|
BR112012004464B8
(pt)
|
2009-08-28 |
2021-05-25 |
Labrys Biologics Inc |
uso de um anticorpo antagonista anti-cgrp para preparar uma composição farmacêutica para tratar e/ou prevenir dor visceral e/ou um ou mais sintomas de dor visceral, em que a dor visceral está associada á cistite intersticial (ic), e dita composição farmacêutica
|
|
JO3330B1
(ar)
|
2010-06-10 |
2019-03-13 |
Lilly Co Eli |
الأجسام المضادة cgrp
|
|
CN108014334B
(zh)
*
|
2011-05-20 |
2021-11-30 |
H.伦德贝克公司 |
抗cgrp抗体和抗体片段用于在有需要的受试者中预防或抑制畏光或厌光的用途
|
|
EA033109B1
(ru)
|
2011-05-20 |
2019-08-30 |
Олдербайо Холдингз Ллк |
Способы ингибирования, профилактики или лечения диареи и/или поддержания соответствующих уровней электролитов и жидкости в толстой кишке субъекта, подвергающегося связанному с диареей состоянию, с помощью антитела против cgrp или фрагмента антитела против cgrp
|
|
PT3495392T
(pt)
*
|
2011-05-20 |
2021-09-22 |
H Lundbeck As |
Composições anti-cgrp e a sua utilização
|
|
US20170114122A1
(en)
|
2015-10-23 |
2017-04-27 |
Alderbio Holdings Llc |
Regulation of glucose metabolism using anti-cgrp antibodies
|
|
MX378344B
(es)
|
2014-03-21 |
2025-03-10 |
Teva Pharmaceuticals Int Gmbh |
Anticuerpos antagonistas dirigidos contra el peptido relacionado con el gen de calcitonina y metodos que usan los mismos.
|
|
GB201408469D0
(en)
|
2014-05-13 |
2014-06-25 |
Obs Medical Ltd |
Method and apparatus for monitoring patient status
|
|
TWI728953B
(zh)
|
2015-04-24 |
2021-06-01 |
美商安美基公司 |
治療或預防偏頭痛之方法
|
|
AR104847A1
(es)
*
|
2015-06-17 |
2017-08-16 |
Lilly Co Eli |
Formulación de anticuerpo anti-cgrp
|
|
JP2018532728A
(ja)
|
2015-09-24 |
2018-11-08 |
テバ・ファーマシューティカルズ・インターナショナル・ゲー・エム・ベー・ハー |
（持続性）外傷後頭痛の予防、治療および低減
|
|
US11596699B2
(en)
*
|
2016-04-29 |
2023-03-07 |
CureVac SE |
RNA encoding an antibody
|
|
SMT202600087T1
(it)
|
2016-09-23 |
2026-03-09 |
Teva Pharmaceuticals Int Gmbh |
Trattamento dell’emicrania refrattaria
|
|
SG11202106878XA
(en)
|
2019-01-08 |
2021-07-29 |
H Lundbeck As |
Treatment of medication overuse headache using anti-cgrp or anti-cgrp-r antibodies
|
|
CR20210373A
(es)
*
|
2019-01-08 |
2021-08-19 |
H Lundbeck As |
Tratamiento agudo y tratamiento rápido de la cefalea usando anticuerpos anti-cgrp
|
|
GEAP202515803A
(en)
|
2019-05-02 |
2025-06-10 |
H Lundbeck As |
Treatment of headache using anti-cgrp antibodies
|
|
EP4034156A4
(en)
|
2019-09-25 |
2024-01-24 |
Allergan Pharmaceuticals International Limited |
COMBINATION THERAPY WITH CGRP ANTAGONISTS
|